Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that both 5% topical and oral minoxidil achieved an 82% hair regrowth response rate in alopecia areata patients, but 5% topical minoxidil was more effective than lower concentrations.

Combination antibiotic therapy is more effective but causes more side effects.

This study suggests that combination therapies including minoxidil with either finasteride, low-level laser light therapy, or microneedling are more effective than minoxidil alone for treating androgenetic alopecia.

This study found that combining oxygen-enriched PRP with minoxidil significantly improved hair density, hair diameter, and follicular density in patients with androgenetic alopecia compared to minoxidil alone, with higher satisfaction scores and only mild, transient adverse effects.

This study found that combined microneedling with minoxidil significantly improved hair count and diameter in patients with androgenetic alopecia, although more mild adverse events were reported compared to minoxidil alone.

This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.

In this retrospective study, cyproterone acetate treatment in late-pubertal trans-girls was found to be generally safe and led to mild feminizing effects, with more rapid feminization occurring when combined with estrogens.

This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.

This study found that combining fractional erbium-glass laser therapy with topical minoxidil significantly improved hair density and diameter in men with androgenetic alopecia compared to using minoxidil alone over a 24-week period, with no serious adverse events reported.

This study found that combining fractional radiofrequency microneedling with 5% topical minoxidil improved hair count and thickness more than minoxidil alone in Chinese men with male pattern hair loss.

This review discusses consensus guidelines for the use of acitretin in psoriasis, highlighting its ongoing utility in both mono and combination therapies, despite not always being recognized in treatment guidelines.

In this study, the authors reported that among patients with androgenetic alopecia, treatment with minoxidil 5% lotion combined with PRP and microneedling resulted in better hair growth and higher satisfaction compared to other treatment groups.

This review found dutasteride to be effective, safe, and well-tolerated for treating symptomatic BPH and provides expert commentary on its use, though the relationship with high-grade prostate cancer remains unclear.

In this case study, combination therapy with dapsone and isotretinoin significantly improved perifolliculitis capitis abscedens et suffodiens, with the patient remaining symptom-free for six months on reduced medication.

In this study, encorafenib combined with binimetinib was well tolerated in melanoma patients, resulting in relatively few cutaneous adverse events compared to other BRAF and MEK inhibitors.

This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.

This review examines the use of tadalafil and finasteride as a combined therapy for BPH, suggesting it may effectively reduce treatment-related sexual adverse events and improve symptom relief.

In this reported case, an immunosuppressive regimen including tacrolimus and mycophenolate mofetil was associated with a total regression of hidradenitis suppurativa activity over one year, while cyclosporine alone had no effect.

In this study, sustained-release sodium valproate showed high efficacy in achieving seizure remission for adults with focal and generalized epilepsy over one year, but side effects like weight gain and tremor were more frequent among heterozygous carriers of certain gene variants.

This study aims to evaluate the efficacy and safety of combining low-dose oral minoxidil with spironolactone for treating female androgenetic alopecia, amid concerns about potential blood pressure effects, though the results are not reported here.

This study suggests that glaucoma patients may face increased risk of optic nerve injury if prescribed medications that can lower blood pressure.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This study found that cyproterone acetate treatment in late-pubertal trans-girls was safe, well-tolerated, and induced mild feminizing changes, with more pronounced effects when combined with estrogens.

Alpha-blocker therapy may not be needed long-term when combined with finasteride for BPH.

In this single-blind clinical trial, adding 1% topical cetirizine to 5% topical minoxidil for 16 weeks did not show improved hair growth outcomes in patients with androgenetic alopecia compared to minoxidil alone, although patient satisfaction was higher with the addition of cetirizine.

In this study, PRP combined with systemic therapy for androgenetic alopecia showed higher, but not statistically significant, improvements in hair density and width compared to PRP alone, with no increase in side effects; further prospective studies are recommended.

This systematic review found no consistent evidence supporting the effectiveness of biotin supplementation for alopecia treatment unless there is a documented deficiency.

This study found that combined microneedling with minoxidil significantly improved hair count and diameter in patients with androgenetic alopecia compared to minoxidil alone, despite mild adverse events, and microneedling parameters like depth and duration did not significantly affect outcomes.

In this study of women with breast cancer undergoing chemotherapy and scalp cooling, 12% experienced incomplete hair regrowth at 6 months, with tamoxifen therapy identified as a significant risk factor for persistent chemotherapy-induced alopecia.